Insmed Announces Topline Results from Phase 1 Study of Treprostinil Palmitil Inhalation Powder (TPIP)PRNewsWire • 02/19/21
Insmed to Host Conference Call to Discuss Topline Data from Treprostinil Palmitil Inhalation Powder Phase 1 StudyPRNewsWire • 02/16/21
Insmed to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on Thursday, February 25, 2021PRNewsWire • 02/12/21
Insmed Receives Priority Medicines (PRIME) Designation from European Medicines Agency (EMA) for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE)PRNewsWire • 11/13/20
Insmed Incorporated (INSM) CEO Will Lewis on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 10/30/20
Insmed Reports Third Quarter 2020 Financial Results and Provides Business UpdatePRNewsWire • 10/29/20
European Commission Grants Marketing Authorization for ARIKAYCE® Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Adult Non-CF Patients with Limited Treatment OptionsPRNewsWire • 10/28/20
Insmed to Host Third Quarter 2020 Financial Results Conference Call on Thursday, October 29, 2020PRNewsWire • 10/20/20
New England Journal of Medicine Publishes Positive Results from Phase 2 WILLOW Study of Brensocatib in Patients with Non-Cystic Fibrosis BronchiectasisPRNewsWire • 09/07/20
Insmed Incorporated (INSM) CEO William Lewis on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/08/20
Insmed Reports Second Quarter 2020 Financial Results and Provides Business UpdatePRNewsWire • 08/06/20
Insmed to Host Second Quarter 2020 Financial Results Conference Call on Thursday, August 6, 2020PRNewsWire • 07/27/20
Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Non-CF Patients with Limited Treatment OptionsPRNewsWire • 07/24/20
New NTM Treatment Guidelines Recommend Insmed's ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of Patients with Refractory MAC Lung DiseasePRNewsWire • 07/07/20
Positive Results from Phase 2 WILLOW Study of Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis Presented at ATS Virtual Clinical Trials SessionPRNewsWire • 06/24/20
Insmed Receives FDA Breakthrough Therapy Designation for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE)PRNewsWire • 06/08/20
Insmed Incorporated (INSM) CEO Will Lewis on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 04/30/20